Le français est une traduction alpha automatisée. Pour le texte officiel, consultez la version anglaise.

Explorateur d’archives

Parcourir et rechercher des captures

Note importante

Parcourez et recherchez des captures historiques. Ceci est une archive — pas des directives actuelles ni un avis médical. Le contenu archivé peut être incomplet, périmé ou remplacé. Pour des recommandations à jour, consultez toujours le site officiel de la source.

Pour plus de contexte sur la couverture et les méthodes de capture, voir Méthodes et couverture.

Parcourir les sites archivés

Parcourir toutes les sources →

Publication of revisions to the Guidance Document - Patented Medicines (Notice of Compliance) Regulations: Notice January 14, 2025 Our reference number: 24-111982-628 Health Canada is pleased to announce an update to the Guidance Document: Patented Medicines (Notice of…

Notice – Implementation of International Council for Harmonisation (ICH) S1B(R1): Testing for Carcinogenicity of Pharmaceuticals January 17, 2025 Our file number: 24-111353 – 179 As a standing regulatory member of the International Council for Harmonisation (ICH), Health Canada…

Qualifying notice amendment for Lumakras (274523) Pharmaceutical Drugs Directorate Holland Cross, Tower "B" 6th Floor, 1600 Scott Street Address Locator #3106B Ottawa ON K1A 0K9 Dossier identifier (ID): HC6-024-e230960 Control number: 274523 Amgen Canada Inc. c/o [name of…

Updates to Mutual Recognition Agreement between Canada and Switzerland Drug Establishment Licensing Bulletin #187, January 31, 2025 On this page Recognition of extra-jurisdictional inspections Recognition of active pharmaceutical ingredients Recognition of stable medicinal…

Salbutamol nebules in short supply: Notice Date published: February 25, 2024 Date updated: February 13, 2026 On this page Background What we're doing What you can do Background Salbutamol is used to relieve symptoms and prevent bronchospasms caused by asthma, bronchitis and other…

What we heard: Draft guidance on expanded access clinical trials On this page Purpose Background Consultation approach Key themes Next steps Contact us Purpose The Draft guidance on expanded access clinical trials was published on August 2, 2024, and opened to the public for…

Notice of Consultation on the Prescription Drug List (PDL): Nicotine Tablets February 13, 2025 Our file number: 25-100875-30 The purpose of this Notice of Consultation is to provide an opportunity for the public and other interested stakeholders to comment on the proposal to…

Notice of Consultation on the Prescription Drug List (PDL): Nicotine Buccal Pouches February 13, 2025 Our file number: 25-100875-30 The purpose of this Notice of Consultation is to provide an opportunity for the public and other interested stakeholders to comment on the proposal…

Drug product database: Terminology - Canada.ca

Health CanadaCaptures 12Dernière capture 11 avr. 2026en

Drug product database: Terminology Active ingredient An Active Ingredient is any component that has medicinal properties and supplies pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment or prevention of disease, or to affect the structure…

Notice of consultation: Removing carisoprodol from the Prescription Drug List Date: February 18, 2025 Our file number: 25-101312-725 This Notice of consultation provides an opportunity to comment on the proposal to remove carisoprodol from the Prescription Drug List (PDL). The…

Page 4290 sur 6399Affichage de 42891 à 42900 sur 63986

Version préliminaire : la couverture et les fonctionnalités sont encore en expansion.